title: Feasibility study of alternate-day S-1 as adjuvant chemotherapy for head and neck cancer.
abstract: OBJECTIVE
  This study analyzed the safety and feasibility of alternate-day S-1, a mixture of tegafur, dehydroxypyrimidine and potassium oxonate, as adjuvant chemotherapy for head and neck cancers.
  
  
  METHODS
  Patients with head and neck squamous cell carcinoma (HNSCC) who underwent primary treatment received alternate-day S-1 (80 mg/day for 1 year). The primary end-point was treatment completion rate. The secondary end-point was adverse events. Three-year overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method.
  
  
  RESULTS
  One-year completion rate was 65.6%. Out of 26 patients, 19.0% had grade III adverse events. All adverse reactions were tolerable and reversible. Three-year OS and DFS were 74.8% and 57.3%, respectively.
  
  
  CONCLUSIONS
  S-1 therapy is an effective adjuvant treatment for head and neck cancer patients with relatively mild side-effects and does not adversely affect quality of life. A phase I/II study is warranted to investigate the appropriate dose for an alternate-day S-1 regimen.
authors: Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors: Yorihisa
authors: Y
authors: Moro
authors: Department of Head and Neck Surgery and Otolaryngology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
authors: Yasunao
authors: Y
authors: Kogashiwa
authors: Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors: Dai
authors: D
authors: Sato
authors: Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors: Yoshifumi
authors: Y
authors: Matsumoto
authors: Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors: Takehiro
authors: T
authors: Nakamura
authors: Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors: Koichi
authors: K
authors: Yamauchi
authors: Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors: Hiroyuki
authors: H
authors: Sakurai
authors: Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan sukohno@ks.kyorin-u.ac.jp.
authors: Naoyuki
authors: N
authors: Kohno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid
keywords: Retrospective study; S-1; oral therapy; toxic effects